Canada markets closed

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.7600+0.0090 (+1.20%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.7510
Bid0.7202 x 100
Ask0.7895 x 100
Day's Range0.7492 - 0.8000
52 Week Range0.7000 - 2.1300
Avg. Volume57,577
Market Cap12.784M
Beta (5Y Monthly)-1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.3700
Earnings DateApr 15, 2024 - Apr 20, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Biomerica provides update on inFoods® IBS expansion

    - Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. - Company receives notice of allowance for five new patents in Europe, Canada and Japan; the inFoods technology now has 25 Issue

  • GlobeNewswire

    Biomerica Reports Third Quarter 2024 Financial Results

    Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syndrome (IBS) Clinical Session Company in discussions with Key Clinical Lab Customers for Use of its Recently US FDA 510(k) Cleared Hp Detect™ Test Product, Designed to Detect the Presence of the H. pylori Bacte

  • GlobeNewswire

    Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference

    Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024